Navigation Links
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Date:9/18/2007

h Products, L.P. In the European Union, Russia, Switzerland and other countries, PREZISTA is marketed by Tibotec, a division of Janssen-Cilag. In Canada, PREZISTA is marketed by Tibotec, a division of Janssen-Ortho Inc. Applications for approval of PREZISTA also have been submitted or are planned for submission in many other countries.

About Tibotec Therapeutics

Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., headquartered in Bridgewater, N.J., is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.

About Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Tibotec Pharmaceuticals is developing a Global Access Program to facilitate access to its antiretrovirals for patients living with HIV/AIDS in developing countries. The Global Access Program for PREZISTA includes access pricing, registration, medical education for appropriate use and voluntary licensing.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, includ
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015   IBA Molecular, a global ... today that it has signed a definitive agreement to ... (IBAM NA), to Illinois Health and Science (IHS). Under IHS ... independent company headquartered in Dulles, Virginia ... of new product and footprint synergies. IBA Molecular is ...
(Date:4/17/2015)... ADELAIDE, Australia , April 17, 2015 ... the discovery and development of innovative therapeutics for the ... system, today announced the presentation of data from three ... American Association for Cancer Research (AACR) 106 th ... Philadelphia, PA USA. ...
(Date:4/16/2015)... drug commonly taken to prevent seizures in epilepsy may surprisingly ... to a study released today that will be presented at ... Washington, DC , April 18 to 25, 2015. ... at some point in their life a condition called acute ... eye to the brain gets inflamed," said study author Raj ...
Breaking Medicine Technology:Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Epilepsy Drug May Preserve Eyesight for People with MS 2
... , SANTA MONICA, Calif. and ... QUOSA, Inc., today announced that Cubist Pharmaceuticals ... between Reprints Desk,s STM Document Delivery service with QUOSA,s ... literature re-use. The integrated solution features integration with ...
... , SOUTH SAN FRANCISCO, Calif., Dec. 9 Anesiva, ... 3, 2009, Anesiva entered into an Asset Purchase Agreement which ... Technologies, Ltd., dated November 30, 2009, and sold certain assets ... British Virgin Island LLC, and Lee,s Pharmaceuticals (HK) Limited (Lee,s ...
Cached Medicine Technology:Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2
(Date:4/18/2015)... (PRWEB) April 18, 2015 Review of ... hosting a ‘Strategies for Success’ program for cataract surgeons ... meeting in San Diego, where eye surgeon Jeffrey L. ... this invitation-only event. Dr. Martin is the Managing Partner ... of Ophthalmology chose Dr. Martin to lead this year’s ...
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... York, NY (PRWEB) April 18, 2015 On ... Internal Security Threat Report , which they say, “exposes a ... how many new malware variants were introduced in 2014 - ... took for Zero Day threats to be identified and patched ... it is abundantly clear that doing business in a digital ...
(Date:4/18/2015)... 18, 2015 French physician and gastronome ... choices when he uttered, “Tell me what you eat, ... food to cope with stress or sadness has often ... indicates otherwise. Data collected from their Emotional ... to emotional eating, but for different reasons. , Collecting ...
(Date:4/17/2015)... Lynnwood, WA (PRWEB) April 17, 2015 ... seat cushions is introducing two new products to help ... seeking low back pain relief are the second most ... was our first product, designed specifically to help relieve ... the Comfort Cushion, and thousands of happy customers later, ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... face increased risk of fractures in later life, particularly ... of The Children's Hospital of Philadelphia and other researchers ... who had first experienced arthritis between ages one and ... a larger control group of 207,000 patients in a ...
... normal lung function and seem to perform lung function ... Similarly, male lung cancer patients were likely to end ... characterized by progressive deterioration in lung function. The results ... journal, a publication of the American College of Chest ...
... in a way that is powerful enough to change public ... continue, it could have a dangerous impact// on real-life situations ... issue of Neurology, the scientific journal of the American Academy ... foreign movies, only two out of 30 movies with characters ...
... in Montreal, Canada, has suggested that mothers who are not ... more attentive mothers. // ,These findings, from ... positive environment not only for the child, but for the ... that applies to our research - the best a father ...
... up by the Indian information technology (IT) sector. This move ... of a BPO firm. // The main aim of the body ... bolster overseas clients that India is safe for business. A lot ... strict surveillance. One such incidence is the arrest of three employees ...
... it was surprising to find that young people in the UK ... infections. // People between the age group of 15-24 years avoid ... As a result of observing the National Condom Week (NAT) health ... the British students. ,It surveyed 2,048 people aged 15 ...
Cached Medicine News:Health News:Male Lung Cancer Patients Less Likely To Perform Well in Lung Function Tests 2Health News:Movies Represent Coma In A Wrong Way 2Health News:Love Mom More 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: